XORTX Therapeutics, Inc. (XRTX)
1.07
-0.03
(-2.73%)
USD |
NASDAQ |
Oct 28, 14:58
XORTX Therapeutics Cash from Operations (Quarterly) : -3.250M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.250M |
| March 31, 2026 | -0.5014M |
| December 31, 2025 | -0.6762M |
| September 30, 2025 | -0.6348M |
| June 30, 2025 | -0.8198M |
| March 31, 2025 | -0.6437M |
| December 31, 2024 | -0.8188M |
| September 30, 2024 | -0.749M |
| June 30, 2024 | -0.7408M |
| March 31, 2024 | -1.304M |
| December 31, 2023 | -1.297M |
| September 30, 2023 | -1.072M |
| June 30, 2023 | -1.728M |
| March 31, 2023 | -2.484M |
| December 31, 2022 | -3.798M |
| September 30, 2022 | -0.9481M |
| June 30, 2022 | -1.862M |
| Date | Value |
|---|---|
| March 31, 2022 | -2.503M |
| December 31, 2021 | -3.136M |
| September 30, 2021 | -0.0613M |
| June 30, 2021 | -0.7021M |
| March 31, 2021 | -0.9237M |
| December 31, 2020 | 0.0269M |
| September 30, 2020 | -0.0898M |
| June 30, 2020 | -0.14M |
| March 31, 2020 | -0.3344M |
| December 31, 2019 | -0.0265M |
| September 30, 2019 | 0.0097M |
| June 30, 2019 | -0.03M |
| March 31, 2019 | -0.0882M |
| December 31, 2018 | -0.0942M |
| September 30, 2018 | -0.1523M |
| June 30, 2018 | -0.2132M |
| March 31, 2018 | -0.2567M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Lexaria Bioscience Corp. | -1.635M |
| InMed Pharmaceuticals, Inc. | -2.909M |
| Target Group, Inc. (Canada) | -0.2229M |
| NervGen Pharma Corp. | -4.086M |
| Milestone Pharmaceuticals, Inc. | -22.53M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.1388M |
| Cash from Financing (Quarterly) | 4.138M |
| Free Cash Flow | -5.239M |
| Free Cash Flow Per Share (Quarterly) | -2.097 |
| Free Cash Flow to Equity (Quarterly) | -3.378M |
| Free Cash Flow to Firm (Quarterly) | -3.393M |
| Free Cash Flow Yield | -370.0% |